Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Bio-Techne, amidst challenging macroeconomic conditions, reported an organic revenue decline of 2% for the second quarter of the fiscal year 2024.</li><li>The healthcare company's earnings were impacted by various headwinds including a cautious biopharma spending environment, a tougher macroeconomic climate in China, and lowered demand from OEM customers.</li><li>Bio-Techne's core portfolio, however, continued to drive the company's long-term growth potential with a 7% average growth rate over the last decade.</li></ul>

Bio-Techne, amidst challenging macroeconomic conditions, reported an organic revenue decline of 2% for the second quarter of the fiscal year 2024.The healthcare company's earnings were impacted by various headwinds including a cautious biopharma spending environment, a tougher macroeconomic climate in China, and lowered demand from OEM customers.Bio-Techne's core portfolio, however, continued to drive the company's long-term growth potential with a 7% average growth rate over the last decade.

Bio-Techne Corporation: A Tale Of Resilience Amid Economic Challenges! - Major Drivers

<ul><li>Bio-Techne Corporation delivered a disappointing set of results as the company was unable to meet Wall Street's revenue and earnings expectations.</li><li>Although the US biopharma funding challenges and evolving macroeconomic conditions in China exceeded initial expectations, Bio-Techne's growth pillars, such as the GMP proteins business, ExoDx prostate, and ProteinSimple franchise, demonstrated robust performance.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Bio-Techne Corporation delivered a disappointing set of results as the company was unable to meet Wall Street's revenue and earnings expectations.Although the US biopharma funding challenges and evolving macroeconomic conditions in China exceeded initial expectations, Bio-Techne's growth pillars, such as the GMP proteins business, ExoDx prostate, and ProteinSimple franchise, demonstrated robust performance.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Bio-Techne Corporation: Impact Of China Funding & Economic Recovery! - Major Drivers

<ul><li>Bio-Techne Corporation concluded the last quarter with a commendable 5% organic growth, mirroring its overall performance for fiscal year 2023.</li><li>Geographically, North America faced headwinds due to reduced biotech funding, while Europe sustained a positive growth trajectory.</li><li>Bio-Techne's success extended to its growth platforms, with the cell and gene therapy business growing over 20% for the fiscal year, underscoring its robust performance in a challenging funding environment.</li></ul>

Bio-Techne Corporation concluded the last quarter with a commendable 5% organic growth, mirroring its overall performance for fiscal year 2023.Geographically, North America faced headwinds due to reduced biotech funding, while Europe sustained a positive growth trajectory.Bio-Techne's success extended to its growth platforms, with the cell and gene therapy business growing over 20% for the fiscal year, underscoring its robust performance in a challenging funding environment.

Bio-Techne Corporation: The Lunaphore Acquisition & Enhanced Spatial Biology Capabilities! - Major Drivers

Equity Capital Markets

<ul><li>Bio-Techne had a weak quarter, with revenues below market expectations.</li><li>Its revenue growth was not up to the mark despite the key drivers being physician uptake, utilization of its ExoDx prostate test, and increased demand for its cell therapy workflow solutions.</li><li>Their Exosome Diagnostics business remained extremely strong in the quarter due to a better marketing message, a stronger commercial team, and the recently modified Medicare LCD, which generated significant test volume and revenue growth.</li></ul>

Bio-Techne had a weak quarter, with revenues below market expectations.Its revenue growth was not up to the mark despite the key drivers being physician uptake, utilization of its ExoDx prostate test, and increased demand for its cell therapy workflow solutions.Their Exosome Diagnostics business remained extremely strong in the quarter due to a better marketing message, a stronger commercial team, and the recently modified Medicare LCD, which generated significant test volume and revenue growth.

Bio-Techne Corporation: Collaboration With Lunaphore & Other Drivers

High Quality Stock Setups, Weekly Stock Bull Finder

Weekly Stock Bull Finder

High Quality Stock Setups

Finding high potential stock setups on quality companies

Thematic (Sector/Industry)

<ul><li>So far in 2023, mega-cap growth names such as Meta, Nvidia, Microsoft, and Netflix have continued to provide market leadership resulting in a 41% YTD gain in the QQQ ETF.</li><li>However, last week saw notable rotation away from technology (XLK) to the healthcare, energy, and financial sectors.</li><li>This came off the backs of notable technology heavyweights Tesla and Netflix earnings reports and investors selling off these names after their earnings prints this week.</li></ul>

So far in 2023, mega-cap growth names such as Meta, Nvidia, Microsoft, and Netflix have continued to provide market leadership resulting in a 41% YTD gain in the QQQ ETF.However, last week saw notable rotation away from technology (XLK) to the healthcare, energy, and financial sectors.This came off the backs of notable technology heavyweights Tesla and Netflix earnings reports and investors selling off these names after their earnings prints this week.

United States

Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.

Bio Techne Corp (TECH US)

Bio-Techne Corporation: A Tale Of Resilience Amid Economic Challenges! - Major Drivers

Bio-Techne, amidst challenging macroeconomic conditions, reported an organic revenue decline of 2% for the second quarter of the fiscal year...

Baptista Research

Bio-Techne Corporation: Impact Of China Funding & Economic Recovery! - Major Drivers

Bio-Techne Corporation delivered a disappointing set of results as the company was unable to meet Wall Street's revenue and earnings...

Baptista Research

Bio-Techne Corporation: The Lunaphore Acquisition & Enhanced Spatial Biology Capabilities! - Major Drivers

Bio-Techne Corporation concluded the last quarter with a commendable 5% organic growth, mirroring its overall performance for fiscal year...

Baptista Research

Bio-Techne Corporation: Collaboration With Lunaphore & Other Drivers

Bio-Techne had a weak quarter, with revenues below market expectations. Its revenue growth was not up to the mark despite the key drivers being...

Baptista Research

Weekly Stock Bullfinder - Week of 7/24

So far in 2023, mega-cap growth names such as Meta, Nvidia, Microsoft, and Netflix have continued to provide market leadership resulting in a 41%...

Weekly Stock Bull Finder